Eri Nakayama

A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19

Yohei Doi, Masaya Hibino, Ryota Hase et al. · Antimicrobial Agents and Chemotherapy · 2020 · 231 citations · Full text

Open-label Trial, Late Favipiravir Therapy, Clinical Infectious Disease +14

Protective Efficacy of Neutralizing Monoclonal Antibodies in a Nonhuman Primate Model of Ebola Hemorrhagic Fever

Andrea Marzi, Reiko Yoshida, Hiroko Miyamoto et al. · PLoS ONE · 2012 · 130 citations · Full text

Veterinary Vaccine, Humoral Response, Immunology +16

Seroepidemiological Prevalence of Multiple Species of Filoviruses in Fruit Bats (<i>Eidolon helvum</i>) Migrating in Africa

Hirohito Ogawa, Hiroko Miyamoto, Eri Nakayama et al. · The Journal of Infectious Diseases · 2015 · 115 citations · Full text

A recombinant platform for flavivirus vaccines and diagnostics using chimeras of a new insect-specific virus

Jody Hobson‐Peters, Jessica J. Harrison, Daniel Watterson et al. · Science Translational Medicine · 2019 · 115 citations

Enzyme-Linked Immunosorbent Assay for Detection of Filovirus Species-Specific Antibodies

Eri Nakayama, Ayaka Yokoyama, Hiroko Miyamoto et al. · Clinical and Vaccine Immunology · 2010 · 114 citations · Full text

Vaccination, Diagnostic Virology, Allergy +12